Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669197 · ClinicalTrials.gov registry record · Phase 2
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
A Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma, sponsored by HonorHealth Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT04669197: Active Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma, sponsored by HonorHealth Research Institute.
NCT04669197 is a Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma that is active but no longer recruiting, run by HonorHealth Research Institute. The registered enrollment target is 19 participants, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04669197, a Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by HonorHealth Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
Primary Outcome
Laboratory measurements of CA 19-9, a circulating tumor biomarker, were collected on Day 1 of every treatment cycle (approximately 21 days/cycle); CA 19-9 normalization after 2 or more treatment cycles was measured.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Hydroxychloroquine
- DRUG Paclitaxel protein bound
Study Locations (1)
Arizona
- HonorHealth Research Institute - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
What the registry record for NCT04669197 still lists
NCT04669197 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (71% lower).
The record links to 3 conditions, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Cisplatin is the first listed.
NCT04669197 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT04669197 about?
NCT04669197 is a clinical study titled "Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer". To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
What is the current status of trial NCT04669197?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2020-12-01. Estimated completion is 2025-12-30.
What conditions does trial NCT04669197 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Untreated Resectable Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT04669197?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Hydroxychloroquine (DRUG), Paclitaxel protein bound (DRUG).
Who is sponsoring clinical trial NCT04669197?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04669197 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04669197's enrollment target sits among peer trials
19 15th of 18 higher than 4 of 18 other Locally Advanced Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Locally Advanced Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
RECRUITING · Phase 2
-
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI